$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

$bmrn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000104847723000020 Filed on April 28, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$595.3M	$596.4M	$519.4M
YoY Change	11.52%	14.84%	6.86%
Cost Of Revenue	$128.1M	$126.5M	$117.0M
YoY Change	4.03%	8.19%	-2.66%
Gross Profit	$467.2M	$469.9M	$402.4M
YoY Change	13.76%	16.77%	9.98%
Gross Profit Margin	78.48%	78.78%	77.48%
Selling, General & Admin	$215.3M	$223.0M	$194.6M
YoY Change	9.4%	14.58%	11.65%
% of Gross Profit	46.09%	47.46%	48.37%
Research & Development	$177.4M	$171.8M	$160.8M
YoY Change	12.12%	6.85%	8.14%
% of Gross Profit	37.96%	36.57%	39.97%
Depreciation & Amortization	$25.42M	$26.42M	$27.34M
YoY Change	167.57%	-3.37%	-2.29%
% of Gross Profit	5.44%	5.62%	6.8%
Operating Expenses	$408.3M	$394.8M	$355.5M
YoY Change	15.01%	11.08%	10.03%
Operating Profit	$58.87M	$59.35M	$137.3M
YoY Change	50.36%	-56.78%	447.42%
Interest Expense	$8.857M	$3.703M	$3.806M
YoY Change	129.52%	-2.71%	0.05%
% of Operating Profit	15.05%	6.24%	2.77%
Other Income/Expense, Net	$3.083M	-$10.83M	-$1.154M
YoY Change	-204.61%	838.47%	-228.22%
Pretax Income	$70.81M	$56.76M	$134.2M
YoY Change	103.18%	-57.7%	477.7%
Income Tax	$14.77M	$5.905M	$13.39M
% Of Pretax Income	20.86%	10.4%	9.98%
Net Earnings	$56.04M	$50.85M	$120.8M
YoY Change	102.57%	-57.9%	595.4%
Net Earnings / Revenue	9.41%	8.53%	23.26%
Basic Earnings Per Share	$0.30	$0.27	$0.66
Diluted Earnings Per Share	$0.29	$0.27	$0.63
COMMON SHARES
Basic Shares Outstanding	187.7M shares	186.5M shares	184.0M shares
Diluted Shares Outstanding	195.0M shares	194.4M shares	194.9M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.171B	$1.152B	$1.056B
YoY Change	5.52%	9.07%	-2.87%
Cash & Equivalents	$694.4M	$580.1M	$605.4M
Short-Term Investments	$476.6M	$572.0M	$450.8M
Other Short-Term Assets	$193.4M	$173.2M	$121.3M
YoY Change	39.1%	42.79%	32.91%
Inventory	$975.5M	$918.9M	$786.4M
Prepaid Expenses
Receivables	$610.2M	$597.9M	$430.1M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.950B	$2.842B	$2.394B
YoY Change	17.18%	18.72%	4.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.067B	$1.068B	$1.040B
YoY Change	1.7%	2.75%	1.67%
Goodwill	$196.2M	$196.2M	$196.2M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$310.3M	$326.0M	$374.3M
YoY Change	-15.98%	-12.9%	-7.8%
Long-Term Investments	$385.8M	$340.6M	$462.8M
YoY Change	-6.48%	-26.4%	44.14%
Other Assets	$1.653B	$150.1M	$149.2M
YoY Change	989.26%	0.58%	5.66%
Total Long-Term Assets	$3.613B	$3.592B	$3.669B
YoY Change	-0.42%	-2.1%	4.33%
TOTAL ASSETS
Total Short-Term Assets	$2.950B	$2.842B	$2.394B
Total Long-Term Assets	$3.613B	$3.592B	$3.669B
Total Assets	$6.563B	$6.434B	$6.063B
YoY Change	6.79%	6.12%	4.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$277.9M	$598.2M	$187.8M
YoY Change	39.49%	218.53%	13.82%
Accrued Expenses	$291.0M	$307.6M	$214.4M
YoY Change	33.37%	43.43%	2.5%
Deferred Revenue			$306.0K
YoY Change			-97.27%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$597.2M	$598.2M	$490.4M
YoY Change	28.51%	21.98%	14.04%
LONG-TERM LIABILITIES
Long-Term Debt	$1.085B	$1.084B	$1.080B
YoY Change	0.37%	0.37%	0.37%
Other Long-Term Liabilities	$98.12M	$92.42M	$100.9M
YoY Change	3.0%	-8.42%	-6.33%
Total Long-Term Liabilities	$1.183B	$92.42M	$100.9M
YoY Change	1141.98%	-8.42%	-6.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$597.2M	$598.2M	$490.4M
Total Long-Term Liabilities	$1.183B	$92.42M	$100.9M
Total Liabilities	$1.780B	$1.775B	$1.671B
YoY Change	8.49%	6.18%	1.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$682.3M	-$738.3M	-$804.9M
YoY Change	-12.21%	-8.27%	-4.66%
Common Stock	$5.494B	$5.418B	$5.206B
YoY Change	4.2%	4.06%	3.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.783B	$4.659B	$4.391B
YoY Change
Total Liabilities & Shareholders Equity	$6.563B	$6.434B	$6.063B
YoY Change	6.79%	6.12%	4.44%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$56.04M	$50.85M	$120.8M
YoY Change	102.57%	-57.9%	595.4%
Depreciation, Depletion And Amortization	$25.42M	$26.42M	$27.34M
YoY Change	167.57%	-3.37%	-2.29%
Cash From Operating Activities	$70.06M	-$73.93M	-$45.43M
YoY Change	24.61%	62.73%	-140.02%
INVESTING ACTIVITIES
Capital Expenditures	$22.73M	$24.46M	$28.82M
YoY Change	-181.08%	-15.13%	12.98%
Acquisitions
YoY Change
Other Investing Activities	$52.26M	-$5.246M	$118.5M
YoY Change	-3240.63%	-104.43%
Cash From Investing Activities	$29.53M	-$30.01M	$87.78M
YoY Change	-199.43%	-134.19%	-224.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.96M	-$40.74M	-$25.28M
YoY Change	-201.55%	61.16%	3.76%
NET CHANGE
Cash From Operating Activities	70.06M	-$73.93M	-$45.43M
Cash From Investing Activities	29.53M	-$30.01M	$87.78M
Cash From Financing Activities	11.96M	-$40.74M	-$25.28M
Net Change In Cash	111.6M	-$144.5M	$18.16M
YoY Change	656.46%	-895.29%	0.05%
FREE CASH FLOW
Cash From Operating Activities	$70.06M	-$73.93M	-$45.43M
Capital Expenditures	$22.73M	$24.46M	$28.82M
Free Cash Flow	$47.33M	-$98.39M	-$74.25M
YoY Change	-43.83%	32.51%	-184.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001048477
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-26727
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BioMarin Pharmaceutical Inc
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	68-0397820
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	770 Lindaro Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Rafael
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94901
CY2023Q1	dei	City Area Code CityAreaCode	415
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	506-6700
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2023Q1	dei	Trading Symbol TradingSymbol	BMRN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	187700942	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	580074000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	724531000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	572017000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	567006000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	597913000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	461316000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	918921000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	894083000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	173180000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	104521000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	2842105000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2751457000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	340635000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	333835000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1068142000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1073366000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	325989000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	338569000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	196199000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	196199000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1510568000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1505412000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	150057000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	176236000	usd
CY2023Q1	us-gaap	Assets Assets	6433695000	usd
CY2022Q4	us-gaap	Assets Assets	6375074000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	598231000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	572959000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	15925000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	598231000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	588884000	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1084006000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1083019000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	92415000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100015000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1774652000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1771918000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	187601106	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	187601106	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	186250719	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	186250719	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	188000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	186000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5417873000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5404895000	usd
CY2023Q1	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	9949000	usd
CY2022Q4	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	8859000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10722000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3867000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-738347000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-789199000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4659043000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4603156000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6433695000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6375074000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	596415000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	519359000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	126549000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	116965000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	171846000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	160836000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	223003000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	194619000	usd
CY2023Q1	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	15670000	usd
CY2022Q1	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	17612000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	108000000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	537068000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	382032000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	59347000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	137327000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	11943000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1820000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3703000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	3806000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-10830000	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1154000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	56757000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	134187000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5905000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13389000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	50852000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	120798000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.66
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	186667000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	183990000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194363000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194886000	shares
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	43997000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	105489000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4603156000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4265669000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4659043000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4386244000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	50852000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	120798000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26421000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27343000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1029000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1033000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1970000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1652000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	53695000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	47833000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	108000000	usd
CY2023Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	12650000	usd
CY2022Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6360000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4800000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-6615000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	6887000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1989000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	222000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-700000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	138796000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	54813000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14098000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1125000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	36001000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	8011000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	323000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1440000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-31686000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-78143000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	4262000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1710000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73932000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45431000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24456000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28817000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	215118000	usd
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	155818000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	220364000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	147361000	usd
CY2023Q1	bmrn	Proceeds From Sale Of Nonfinancial Assets ProceedsFromSaleOfNonfinancialAssets	0	usd
CY2022Q1	bmrn	Proceeds From Sale Of Nonfinancial Assets ProceedsFromSaleOfNonfinancialAssets	110000000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	310000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1858000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-30012000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	87782000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	21169000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8235000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	51422000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	32949000	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	9475000	usd
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1014000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	566000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-40742000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-25280000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	229000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1093000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-144457000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	18164000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	724531000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	587276000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580074000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	605440000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1437000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1422000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	4364000	usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1316000	usd
CY2023Q1	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets	-8430000	usd
CY2022Q1	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets	-2481000	usd
CY2023Q1	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets	-1478000	usd
CY2022Q1	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets	-637000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div>
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1503247000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	644000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11165000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1492726000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	580074000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	572017000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	340635000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1641139000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	159000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15926000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1625372000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	724531000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	567006000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	333835000	usd
CY2023Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	12600000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	138933000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	131071000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	437109000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	410656000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	342879000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	352356000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	918921000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	894083000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1875086000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1875511000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	806944000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	802145000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1068142000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1073366000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	10300000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	11700000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	693356000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	690871000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	367367000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	352302000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	325989000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	338569000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	264778000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	231238000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	134372000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	207573000	usd
CY2023Q1	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	87761000	usd
CY2022Q4	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	72654000	usd
CY2023Q1	bmrn	Accrued Loss Contingency Current AccruedLossContingencyCurrent	39000000	usd
CY2022Q4	bmrn	Accrued Loss Contingency Current AccruedLossContingencyCurrent	0	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	22387000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	16213000	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15956000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	12601000	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	14797000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13306000	usd
CY2023Q1	bmrn	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	9251000	usd
CY2022Q4	bmrn	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	10375000	usd
CY2023Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	9929000	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	8999000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	598231000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	572959000	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	15594000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	22995000	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	18100000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	13675000	usd
CY2023Q1	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	-1700000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1100000000	usd
CY2023Q1	us-gaap	Convertible Debt ConvertibleDebt	1084006000	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	1083019000	usd
CY2023Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1130971000	usd
CY2022Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1173600000	usd
CY2023Q1	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	-2612000	usd
CY2023Q1	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	3014000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	1229000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6855000	usd
CY2022Q1	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	-13499000	usd
CY2022Q1	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	4193000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-2383000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15309000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	596415000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	519359000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	53695000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47833000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	50852000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	120798000	usd
CY2023Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	937000	usd
CY2022Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	2763000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	51789000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	123561000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	186667000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	183990000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194363000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194886000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.66
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12975000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10927000	shares
CY2023Q1	bmrn	Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones	762500000	usd
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	251700000	usd
CY2023Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	205900000	usd

Files In Submission

Name	View Source	Status
0001048477-23-000020-index-headers.html	Edgar Link	pending
0001048477-23-000020-index.html	Edgar Link	pending
0001048477-23-000020.txt	Edgar Link	pending
0001048477-23-000020-xbrl.zip	Edgar Link	pending
bmrn-20230331.htm	Edgar Link	pending
bmrn-20230331.xsd	Edgar Link	pending
bmrn-exx311xq12023.htm	Edgar Link	pending
bmrn-exx312xq12023.htm	Edgar Link	pending
bmrn-exx321xq12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
bmrn-20230331_cal.xml	Edgar Link	unprocessable
bmrn-20230331_lab.xml	Edgar Link	unprocessable
bmrn-20230331_def.xml	Edgar Link	unprocessable
bmrn-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bmrn-20230331_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2023 Q2 Form 10-Q Financial Statement

#000104847723000020 Filed on April 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2023 Q2 Form 10-Q Financial Statement

#000104847723000020 Filed on April 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn